AI is more accessible today than ever before and is rapidly becoming a critical launch enabler. While emerging biotech companies have the opportunity to embed AI into new operating models from day one, established organizations often face the challenge of integrating AI into existing processes, systems, and ways of working. This panel brings together leaders from emerging and established biopharma and AI strategy firms to explore where and how AI is creating real value in launch planning and execution, what remains overhyped, and how organizations can move from experimentation to practical impact. Attend this session to:
Identify where AI can most effectively improve launch efficiency, insights, and decision-making
Understand how AI strategy, enablement and adoption differs between emerging launch organizations and established commercial teams
Learn a practical AI framework for characterizing AI opportunities and overcoming common barriers to implementation
Check out the incredible speaker line-up to see who will be joining Liz.
The browser you are using is not supported that will prevent you from accessing certain features of the website. We want you to have the best possible experience. For this you'll need to use a supported browser and upgrade to the latest version.